TMEM106A as a Macrophage‐Associated Biomarker of Prognosis in IDH ‐Wildtype Glioma: Integrative Multi‐Omics and Spatial Analyses
Cancer Medicine · 2025
DOI: 10.1002/cam4.71454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Wen-Shin Song und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurosurgery, Department of Surgery, Cheng-Hsin General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Glioma, Membrane Proteins, Biomarkers, Tumor, Brain Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Tri-Service General Hospital, Ministry of National Defense Medical Affairs Bureau.
Abstract (Originalsprache)
Introduction
Gliomas remain aggressive despite current therapies, highlighting the urgent need for new biomarkers and targets. Transmembrane protein 106A (TMEM106A), implicated as a tumor suppressor in various cancers, has an unclear role in gliomas. We hypothesized that TMEM106A expression associates with tumor aggressiveness and may serve as a prognostic, microenvironmental biomarker.
Methods
We integrated TCGA and CGGA bulk RNA‐seq, single‐cell (GSE131928, GSE89567), spatial (Ivy Atlas, Visium), and immunohistochemistry ( n = 79) to evaluate TMEM106A. Differential expression used limma. Survival used Kaplan–Meier and multivariable Cox models. Immune contexture used a 12‐cell‐state deconvolution and CIBERSORT. GSEA assessed hallmark pathways. Drug sensitivity was inferred using pRRophetic. Immunotherapy modeling combined TCGA expression with TCIA immunophenoscore and PD‐L1.
Results
(1) TMEM106A mRNA is significantly upregulated in high‐grade gliomas compared to lower‐grade gliomas and normal brain. (2) In IDH‐wildtype tumors, differential analyses highlight roles of TMEM106A and TMEM106C; high expression links to poorer prognosis. (3) TMEM106A is an independent prognostic factor associated with aggressive behavior, especially in IDH‐wildtype astrocytomas. (4) Upregulation is confirmed by immunohistochemistry. (5) High TMEM106A associates with pro‐inflammatory signatures and higher inferred fractions of myeloid cells and granulocytes. (6) Single‐cell RNA‐seq shows enrichment in myeloid lineages, and (7) CIBERSORT shows modest positive correlations with polarized macrophage signatures. (8) Spatial transcriptomics shows higher TMEM106A in myeloid‐rich regions, consistent with a microenvironmental readout. (9) In IDH‐wildtype tumors, pRRophetic predicts lower IC50 for multiple targeted agents in TMEM106A‐high tumors. (10) TMEM106A‐high IDH‐wildtype tumors show higher IPS only when PD‐1 is “on,” suggesting a context‐dependent, inflamed‐but‐suppressed state.
Conclusion
TMEM106A independently predicts survival and correlates with myeloid‐enriched transcriptional states in gliomas. Given its high expression in myeloid lineages in single‐cell data, bulk upregulation is potentially driven by myeloid infiltration rather than tumor‐cell intrinsic mechanisms. All findings are correlative; prospective studies are needed before any clinical use is considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurosurgery, Department of Surgery, Cheng-Hsin General Hospital, Taipei, Taiwan.
- Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
- Graduate Institute of Life Sciences, National Defense Medical University, Taipei, Taiwan.
- Graduate Institute of Pathology and Parasitology, National Defense Medical University, Taipei, ROC, Taiwan.
- Department of Pathology, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
ORCID-Profile: Yao-Feng Li
Förderung
- National Science and Technology Council
- Tri-Service General Hospital
- Ministry of National Defense Medical Affairs Bureau
- Cheng-Hsin General Hospital & National Defense Medical Center
Zitieren
APA
Song, W. S., Chang, P. C., Hueng, D. Y., & Li, Y. F. (2025). TMEM106A as a Macrophage‐Associated Biomarker of Prognosis in IDH ‐Wildtype Glioma: Integrative Multi‐Omics and Spatial Analyses. Cancer Medicine. https://doi.org/10.1002/cam4.71454
Vancouver
Song WS, Chang PC, Hueng DY, Li YF. TMEM106A as a Macrophage‐Associated Biomarker of Prognosis in IDH ‐Wildtype Glioma: Integrative Multi‐Omics and Spatial Analyses. Cancer Medicine. 2025. doi:10.1002/cam4.71454
BibTeX
@article{Song2025,
author = {Song, Wen-Shin and Chang, Pei-Chi and Hueng, Dueng-Yuan and Li, Yao-Feng},
title = {TMEM106A as a Macrophage‐Associated Biomarker of Prognosis in IDH ‐Wildtype Glioma: Integrative Multi‐Omics and Spatial Analyses},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71454}
}
EUVIMED